{"id":"metronidazole-250-14-days","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Metallic taste"},{"rate":"5-15","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"1-2","effect":"Peripheral neuropathy"},{"rate":null,"effect":"Disulfiram-like reaction with alcohol"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metronidazole is a prodrug that is activated by anaerobic organisms and parasites to form reactive intermediates that bind to and cleave DNA, preventing replication and transcription. It is effective against anaerobic bacteria and certain protozoan parasites. The drug is particularly useful in infections where oxygen is limited, as it requires anaerobic conditions for activation.","oneSentence":"Metronidazole disrupts bacterial and parasitic DNA by generating reactive oxygen species and damaging their genetic material.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:06.203Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anaerobic bacterial infections"},{"name":"Trichomoniasis"},{"name":"Giardiasis"},{"name":"Amebiasis"},{"name":"Clostridioides difficile infection"},{"name":"Bacterial vaginosis"}]},"trialDetails":[{"nctId":"NCT05332444","phase":"PHASE4","title":"Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-11","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT04554693","phase":"PHASE4","title":"The Use of Low Dose Metronidazole to Decrease Postoperative Pain After Endometriosis Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Louisville","startDate":"2020-10-19","conditions":"Endometriosis, Endometriosis-related Pain","enrollment":90},{"nctId":"NCT06509139","phase":"PHASE4","title":"Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males","status":"ENROLLING_BY_INVITATION","sponsor":"National Cheng-Kung University Hospital","startDate":"2024-07-09","conditions":"Helicobacter Pylori Infection, Sex, Bismuth Quadruple Therapy","enrollment":661},{"nctId":"NCT04527055","phase":"PHASE4","title":"The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication","status":"ENROLLING_BY_INVITATION","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-05-06","conditions":"Helicobacter Pylori Infection, Dysbiosis, Probiotics","enrollment":312},{"nctId":"NCT03779074","phase":"PHASE3","title":"Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2018-09-03","conditions":"Helicobacter Pylori Infection","enrollment":918},{"nctId":"NCT03830333","phase":"PHASE3","title":"Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-03-20","conditions":"Complicated Intra-abdominal Infections","enrollment":268},{"nctId":"NCT03458663","phase":"NA","title":"Randomized Trial Comparing Prevena and ActiV.A.C. System to Convetional Care After Bascom's Cleft Lift Surgery","status":"TERMINATED","sponsor":"University of Aarhus","startDate":"2019-01-14","conditions":"Pilonidal Disease","enrollment":106},{"nctId":"NCT02606032","phase":"PHASE2","title":"Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative Colitis","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2016-05","conditions":"Ulcerative Colitis","enrollment":75},{"nctId":"NCT02646332","phase":"NA","title":"Comparing the Efficacy of Reverse Hybrid Therapy and Concomitant Therapy","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2015-12","conditions":"Helicobacter Pylori Infection","enrollment":248},{"nctId":"NCT02490839","phase":"PHASE4","title":"Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for Rescue Treatment of Hp Infection","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-07","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT02735395","phase":"PHASE4","title":"Dose and Duration of Metronidazole and Amoxicillin for Treatment of Chronic Periodontitis","status":"UNKNOWN","sponsor":"University of Guarulhos","startDate":"2011-07","conditions":"Chronic Periodontitis","enrollment":110},{"nctId":"NCT02547038","phase":"NA","title":"Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2015-02","conditions":"Helicobacter Pylori Infection","enrollment":352},{"nctId":"NCT02483715","phase":"PHASE4","title":"Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for First-line Treatment of Hp Infection","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-07","conditions":"Helicobacter Pylori Infection","enrollment":589},{"nctId":"NCT03727620","phase":"PHASE1, PHASE2","title":"Doxycycline in the Treatment of Aggressive Periodontitis","status":"COMPLETED","sponsor":"Mohammed V Souissi University","startDate":"2014-01-06","conditions":"Aggressive Periodontitis","enrollment":24},{"nctId":"NCT02739997","phase":"PHASE3","title":"Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-04-08","conditions":"Intra-abdominal Infection, Complicated Intra-abdominal Infection","enrollment":100},{"nctId":"NCT01160640","phase":"PHASE2","title":"The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)","status":"COMPLETED","sponsor":"Harold Wiesenfeld","startDate":"2010-11","conditions":"Pelvic Inflammatory Disease","enrollment":233},{"nctId":"NCT02541864","phase":"NA","title":"Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2013-07","conditions":"Helicobacter Pylori Infection","enrollment":330},{"nctId":"NCT01725906","phase":"PHASE4","title":"Genotypic Resistance Guided Therapy in Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2012-11","conditions":"Self Efficacy","enrollment":450},{"nctId":"NCT02422706","phase":"PHASE3","title":"Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2015-01","conditions":"Helicobacter-associated Gastritis","enrollment":120},{"nctId":"NCT01163435","phase":"PHASE4","title":"Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2010-08","conditions":"Helicobacter Infection","enrollment":618},{"nctId":"NCT00066066","phase":"PHASE2","title":"Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers","status":"COMPLETED","sponsor":"The Forsyth Institute","startDate":"2003-07","conditions":"Periodontitis, Periodontal Diseases","enrollment":146},{"nctId":"NCT01098448","phase":"PHASE3","title":"Control of Periodontal Infections","status":"COMPLETED","sponsor":"The Forsyth Institute","startDate":"1999-09","conditions":"Periodontitis","enrollment":187}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Metronidazole 250 (14 days)","genericName":"Metronidazole 250 (14 days)","companyName":"University of Guarulhos","companyId":"university-of-guarulhos","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metronidazole disrupts bacterial and parasitic DNA by generating reactive oxygen species and damaging their genetic material. Used for Anaerobic bacterial infections, Trichomoniasis, Amebiasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}